U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472413) titled 'Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project' on Feb. 24.
Brief Summary: The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.
Study Start Date: July 01, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis
Intervention: ...